Riley Maintains ‘Buy’ Rating on Lantheus Holdings, Inc. (LNTH); Lowers PT

Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best stocks for a Growth Stock Portfolio.

A pharmacist in their lab coat preparing a drug-free nasal spray for distribution.

Riley lowered its price target on LNTH from $122 to $109, maintaining a ‘Buy’ rating on June 24, 2025. This reduction follows the company’s profitability pressures despite the top-line growth. On one hand, the revenue for Q1 2025 rose 0.8% YoY, while on the other hand, adjusted earnings per share (EPS) fell by 9.5% to $1.53 per share.

Meanwhile, Lantheus Holdings, Inc. (NASDAQ:LNTH) is making strategic moves amid margin pressures. Its strategic moves include the acquisition of Evergreen Theragnostics and Life Molecular Imaging. Looking ahead, the company plans to divest from its SPECT segment to SHINE Technologies. These initiatives highlight the company’s efforts to reinforce its PET-focused pipeline and strengthen its long-term position in radiotherapeutics.

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a developer of radiopharmaceutical and imaging solutions. Its portfolio consists of PET imaging agents like PYLARIFY, ultrasound contrast DEFINITY, and AI-driven imaging software.

While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.

Source link